5-羟色胺在非酒精性脂肪性肝病发病机制及治疗中的作用

金豆; 牛春燕

doi:10.3969/j.issn.1001-5256.2017.06.033

5-羟色胺在非酒精性脂肪性肝病发病机制及治疗中的作用

DOI: 10.3969/j.issn.1001-5256.2017.06.033

金豆,
牛春燕

1. 西安医学院
2. 西安医学院第一附属医院消化内科

基金项目:

陕西省教育厅科学研究项目计划(2013JK0788)；陕西省普通高等学校优势学科(陕教位[2014]3号文件)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2105
- HTML全文浏览量: 37
- PDF下载量: 454
- 被引次数: 0
出版历程
- 出版日期: 2017-06-20

Role of 5-hydroxytryptamine in the pathogenesis and treatment of nonalcoholic fatty liver disease

Xi'an Medical College

Research funding:

摘要

摘要: 非酒精性脂肪性肝病（NAFLD）的患病率不断上升,其发病机制复杂且尚未完全阐明,迄今仍缺乏诊断及治疗的金标准,5-羟色胺可以从多个环节影响NAFLD的发生、发展,改变NAFLD的疾病进程。现从能量代谢、肠道通透性及肠道菌群失调、肝脏再生的角度阐述5-羟色胺与NAFLD的相关性及其在NAFLD发病机制中的作用及治疗中的应用前景。
- 脂肪肝 /
- 血清素 /
- 综述
Abstract: The prevalence rate of nonalcoholic fatty liver disease (NAFLD) has been increasing year by year. However, since the complex pathogenesis of NAFLD has not been fully clarified, there still lacks a gold standard for the diagnosis and treatment of NAFLD. 5-Hydroxytryptamine (5-HT) can affect the development and progression of NAFLD via several links and thus change the course of NAFLD.This article introduces the association between 5-HT and NAFLD, the role of 5-HT in the pathogenesis of NAFLD, and its future application in treatment.
- fatty liver /
- serotonin /
- review

HTML全文

参考文献(48)

[1]VUPPALANCHI R, CHALASANI N.Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis:selected practical issues in their evaluation and management[J].Hepatology, 2009, 49 (1) :306-317.

[2]LIU YF, XIE W.Advances in the treatment of non-alcoholic fatty liver disease[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (1) :26-28. (in Chinese) 刘玉凤, 谢雯.非酒精性脂肪性肝病治疗进展[J/CD].中国肝脏病杂志:电子版, 2016, 8 (1) :26-28.

[3]BYRNE CD, TARGHER G.NAFLD:a multisystem disease[J].J Hepatol, 2015, 62 (1 Suppl) :s47-s64.

[4]BUZZETTI E, PINZANI M, TSOCHATZIS EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J].Metabolism, 2016, 65 (8) :1038-1048.

[5]YOUNG RL, LUMSDEN AL, KEATING DJ.Gut serotonin is a regulator of obesity and metabolism[J].Gastroenterology, 2015, 149 (1) :253-255.

[6]HERNANDEZ LL, LIMESAND SW, COLLIER JL, et al.The bovine mammary gland expresses multiple functional isoforms of serotonin receptors[J].J Endocrinol, 2009, 203 (1) :123-131.

[7]LAPORTA J, PETERS TL, WEAVER SR, et al.Feeding 5-hydroxy-l-tryptophan during the transition from pregnancy to lactation increases calcium mobilization from bone in rats[J].Domest Anim Endocrinol, 2013, 44 (4) :176-184.

[8]LAPORTA J, PETERS TL, MERRIMAN KE, et al.Serotonin (5-HT) affects expression of liver metabolic enzymes and mammary gland glucose transporters during the transition from pregnancy to lactation[J].PLo S One, 2013, 8 (2) :e57847.

[9]BRINDLEY RL, BAUER MB, BLAKELY RD, et al.An interplay between the serotonin transporter (SERT) and 5-HT receptors controls stimulus-secretion coupling in sympathoadrenal chromaffin cells[J].Neuropharmacology, 2016, 110 (Pt A) :438-448.

[10]GU QY, ZHANG J.The progress of the correlation between 5-hydroxytryptamine and functional dyspepsia[J].Med J West China, 2015, 27 (1) :155-158. (in Chinese) 古巧燕, 张军.5羟色胺与功能性消化不良相关性研究进展[J].西部医学, 2015, 27 (1) :155-158.

[11]ERSPAMER V, ASERO B.Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine[J].Nature, 1952, 169 (4306) :800-801.

[12]RUDDELL RG, MANN DA, RAMM GA.The function of serotonin within the liver[J].J Hepatol, 2008, 48 (4) :666-675.

[13]SULLO A, BRIZZI G, MAFFULLI N.Chronic peripheral administration of serotonin inhibits thyroid function in the rat[J].Muscles Ligaments Tendons J, 2011, 1 (2) :48-50.

[14]LIU Q, YANG Q, SUN W, et al.Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract[J].J Pharmacol Exp Ther, 2008, 325 (1) :47-55.

[15]YADAV VK, BALAJI S, SURESH PS, et al.Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis[J].Nat Med, 2010, 16 (3) :308-312.

[16]GERSHON MD.Review article:serotonin receptors and transporters—roles in normal and abnormal gastrointestinal motility[J].Aliment Pharmacol Ther, 2004, 20 (Suppl 7) :3-14.

[17]HAUB S, KANURI G, VOLYNETS V, et al.Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice[J].Am J Physiol Gastrointest Liver Physiol, 2010, 298 (3) :g335-g344.

[18]RITZE Y, BHLE M, HAUB S, et al.Role of serotonin in fatty acid-induced non-alcoholic fatty liver disease in mice[J].BMC Gastroenterol, 2013, 13:169.

[19]WATANABE H, AKASAKA D, OGASAWARA H, et al.Peripheral serotonin enhances lipid metabolism by accelerating bile acid turnover[J].Endocrinology, 2010, 151 (10) :4776-4786.

[20]SUMARA G, SUMARA O, KIM JK, et al.Gut-derived serotonin is a multifunctional determinant to fasting adaptation[J].Cell Metab, 2012, 16 (5) :588-600.

[21]KIM HJ, KIM JH, NOH S, et al.Metabolomic analysis of livers and serum from high-fat diet induced obese mice[J].J Proteome Res, 2011, 10 (2) :722-731.

[22]KWAK SH, PARK BL, KIM H, et al.Association of variations in TPH1 and HTR2B with gestational weight gain and measures of obesity[J].Obesity (Silver Spring) , 2012, 20 (1) :233-238.

[23]KIM SH, PLUTZKY J.Brown fat and browning for the treatment of obesity and related metabolic disorders[J].Diabetes Metab J, 2016, 40 (1) :12-21.

[24]FISLER JS, WARDEN CH.Uncoupling proteins, dietary fat and the metabolic syndrome[J].Nutr Metab (Lond) , 2006, 3:38.

[25]CAO W, MEDVEDEV AV, DANIEL KW, et al.beta-Adrenergic activation of p38 MAP kinase in adipocytes:c AMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase[J].J Biol Chem, 2001, 276 (29) :27077-27082.

[26]THONBERG H, FREDRIKSSON JM, NEDERGAARD J, et al.A novel pathway for adrenergic stimulation of c AMP-response-element-binding protein (CREB) phosphorylation:mediation via alpha1-adrenoceptors and protein kinase C activation[J].Biochem J, 2002, 364 (Pt 1) :73-79.

[27]HARMS M, SEALE P.Brown and beige fat:development, function and therapeutic potential[J].Nat Med, 2013, 19 (10) :1252-1263.

[28]CRANE JD, PALANIVEL R, MOTTILLO EP, et al.Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis[J].Nat Med, 2015, 21 (2) :166-172.

[29]SEMPLE RK, SLEIGH A, MURGATROYD PR, et al.Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis[J].J Clin Invest, 2009, 119 (2) :315-322.

[30]KIEFER FW, VERNOCHET C, O'BRIEN P, et al.Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue[J].Nat Med, 2012, 18 (6) :918-925.

[31]ROBERTS LD, BOSTRM P, O'SULLIVAN JF, et al.β-Aminoisobutyric acid induces browning of white fat and hepaticβ-oxidation and is inversely correlated with cardiometabolic risk factors[J].Cell Metab, 2014, 19 (1) :96-108.

[32]QIU Y, NGUYEN KD, ODEGAARD JI, et al.Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat[J].Cell, 2014, 157 (6) :1292-1308.

[33]LAPORTA J, MOORE SA, WEAVER SR, et al.Increasing serotonin concentrations alter calcium and energy metabolism in dairy cows[J].J Endocrinol, 2015, 226 (1) :43-55.

[34]PAULMANN N, GROHMANN M, VOIGT JP, et al.Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation[J].PLo S Biol, 2009, 7 (10) :e1000229.

[35]YAMADA T, INUI A, HAYASHI N, et al.Serotonin stimulates endotoxin translocation via 5-HT3 receptors in the rat ileum[J].Am J Physiol Gastrointest Liver Physiol, 2003, 284 (5) :g782-g788.

[36]COPE K, RISBY T, DIEHL AM.Increased gastrointestinal ethanol production in obese mice:implications for fatty liver disease pathogenesis[J].Gastroenterology, 2000, 119 (5) :1340-1347.

[37]LI Z, YANG S, LIN H, et al.Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease[J].Hepatology, 2003, 37 (2) :343-350.

[38]BRUN P, CASTAGLIUOLO I, DI LV, et al.Increased intestinal permeability in obese mice:new evidence in the pathogenesis of nonalcoholic steatohepatitis[J].Am J Physiol Gastrointest Liver Physiol, 2007, 292 (2) :g518-g525.

[39]BERGHEIM I, WEBER S, VOS M, et al.Antibiotics protect against fructose-induced hepatic lipid accumulation in mice:role of endotoxin[J].J Hepatol, 2008, 48 (6) :983-992.

[40]HAUB S, RITZE Y, LADEL I, et al.Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice[J].J Pharmacol Exp Ther, 2011, 339 (3) :790-798.

[41]WIGG AJ, ROBERTS-THOMSON IC, DYMOCK RB, et al.The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis[J].Gut, 2001, 48 (2) :206-211.

[42]SEKI E, BRENNER DA.Toll-like receptors and adaptor molecules in liver disease:update[J].Hepatology, 2008, 48 (1) :322-335.

[43]KAWAI T, AKIRA S.The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J].Nat Immunol, 2010, 11 (5) :373-384.

[44]LATORRE E, LAYUNTA E, GRASA L, et al.Intestinal serotonin transporter inhibition by toll-like receptor 2 activation.A feedback modulation[J].PLo S One, 2016, 11 (12) :e0169303.

[45]LESURTEL M, GRAF R, ALEIL B, et al.Platelet-derived serotonin mediates liver regeneration[J].Science, 2006, 312 (5770) :104-107.

[46]PANG Q, LIU C, ZHANG JY, et al.Serotonin in liver tumor:Friend or foe[J].Hepatology, 2015, 62 (1) :319.

[47]LESURTEL M, CLAVIEN PA.Platelet-derived serotonin:translational implications for liver regeneration[J].Hepatology, 2014, 60 (1) :30-33.

[48]REIGSTAD CS, SALMONSON CE, RAINEY JF, et al.Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells[J].FASEB J, 2015, 29 (4) :1395-1403.

施引文献

资源附件(0)

访问统计